Evaluation of efficacy and tolerability of curcumin enemas in ulcerative colitis -

Dr Vinnet Ahuja0 个研究点目标入组 96 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Adult patients
•2. Mild-to-moderately active proctitis and proctosigmoiditis (Ulcerative Colitis Disease Activity Index [UCDAI] score, 3-9), with endoscopic disease extent up to 25 cm from the anal verge
•3.Patients receiving mesalamine if the dose is stable for more than 8 weeks

•1.Patients receiving rectal mesalamine or steroids during last 4 weeks
•2.Disease extent more than proctosigmoiditis, evidence of severe disease (UCDAI more than 10)
•3.Steroid initiation/dose escalation within the past 2 weeks,
•4. Azathioprine initiation in past 6 months or change in dose of azathioprine in last 3 months.
•5.History of Patients started on mesalamine in the past 8 weeks.
•6. Patients requiring hospitalization and imminent need for surgery
•7.Lactating and pregnant women
•8.Patients received any investigational medicines within 3 months
•9.Patients with significant hepatic, renal, endocrine, respiratory, neurologic, or cardiovascular diseases

发起方

Dr Vinnet Ahuja